ArticleFrontiers in immunology2025
New serum soluble factors predicting inflammatory and non-inflammatory disability worsening in multiple sclerosis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Selected Cytokines and Matrix Metalloproteinases in Pathogenesis and Treatment of Multiple Sclerosis.International journal of molecular sciences · 2026Review
- CSF Cytokine Network Organization Predicts Progression Independent of Relapse and MRI Activity in Multiple Sclerosis.Annals of clinical and translational neurology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Serum neurofilament light chains (sNfL) and glial fibrillary acidic protein (sGFAP) associate respectively with acute inflammation and smoldering disease in relapsing-remitting multiple sclerosis (MS) patients. We explored the proteomic profile associated with the different combinations of low or high levels of sNfL and sGFAP to explore immune mechanisms involved in different MS outcomes. Methods: Multicenter cross-sectional study including 253 treatment-naïve PwMS, and 180 healthy controls (HCs). sNfL and sGFAP levels were measured via SIMOA and patients were classified according to their levels into four groups: NLGL (normal sNfL and sGFAP), NHGL (high sNfL/normal sGFAP), NHGH (high sNfL and sGFAP), and NLGH (normal sNfL/high sGFAP). Serum proteomics were measured using the Olink™ 48 Cytokine panel. Results were analyzed by Kruskal-Wallis tests with Dunn's Results: Compared with HC, patients with low sGFAP concentrations exhibited decreased levels of granulocyte-macrophage colony stimulating factor (GM-CSF), a cytokine inducing innate cell activation q=0.009 for NLGL and q=0.002 for NHGL groups). Conversely, patients with high sGFAP values showed a remarkable decrease of epidermal growth factor (EGF), a cytokine involved in remyelination and axon repair produced by resting astroglia (q<0.0001 for NHGH and NLGH respectively). Additionally, NLGH patients exhibited pronounced decreases in soluble mediators essential for adaptive immune activation, including FLT3LG, TNFSF12, and TNF-α, compared to HC. They also showed broad reductions in chemokines involved in leukocyte recruitment as CCL3, CCL7, and CCL4. The most important decrease was found in CCL2, a chemokine that attracts monocytes and memory T cells to the CNS. NLGH patients showed lower values than HC (q<0.0001), NLGL (q=0.02), NHGL (q=0.02), and NHGH (q=0.03). These findings indicated that NLGH patients experience a reduction of the inflammatory response in the peripheral blood and a decreased immune cell attraction to the central nervous system combined with a lower ability of tissue repair. Discussion: We identified new molecules implied in the different pathological mechanisms occurring in patients with MS. These biomarkers could improve patient stratification, outcome prediction, and treatment optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.